Skip to main content

Genoptix Licenses Rights to HistoRx Aqua Tech

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Lab services provider Genoptix said today that it has signed a license and collaboration agreement with HistoRx covering cancer biomarker analysis technologies in the US.

The license gives Carlsbad, Calif.-based Genoptix the exclusive commercial laboratory rights to develop and perform in the US three solid tumor assays using HistoRx's Aqua technology. In addition, it has gained non-exclusive rights to use Aqua to measure two other biomarkers that have been associated with many cancers.

The Aqua technology is used in fluorescent immunohistochemstry analysis, and enables users to assess specific biomarkers for patients with solid tumors by measuring the protein in a cell's cytoplasm or nucleus.

Under the agreement, Genoptix and HistoRx may collaborate to develop additional assays that Genoptix would then have the rights to commercialize. Financial terms of the agreement were not released.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.